A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis
Recruiting now · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Bronchiectasis
In brief
The aim of this clinical trial is to assess the safety of: * single doses of the study drug CHF6333 in Healthy Volunteers (HVs) and in subjects with Bronchiectasis (BE) - Part I * repeated doses of the study drug CHF6333 in subjects with BE - Part II
Key facts
- Study ID
- NCT06166056
- Run by
- Chiesi Farmaceutici S.p.A.
- People needed
- 45
- Starts
- 2023-11-29
- Expected to finish
- 2026-08-01
- Last updated by the study team
- 2026-03-05
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.
Where it is running
- Royal Papworth Hospital NHS Foundation Trust, Cambridge Centre for Lung Infection — Cambridge, United Kingdom (enrolling)
- Tayside Medical Science Centre, Ninewells Hospital & Medical School — Dundee, United Kingdom (enrolling)
- NHS Lothian — Edinburgh, United Kingdom (enrolling)
- Glasgow Royal Infirmary — Glasgow, United Kingdom (enrolling)
- University Hospital Southampton NHS Foundation Trust — Southampton, United Kingdom (enrolling)
- Royal Bromptom Hospital (NHS Guy's and Thomas') — London, United Kingdom (enrolling)
- Manchester University NHS Foundation Trust — Manchester, United Kingdom (enrolling)
- Medicines Evaluation Unit (MEU) — Manchester, United Kingdom (enrolling)
- The Leeds Teaching Hospitals NHS Trust, Saint James's University Hospital — Leeds, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.